Biogen Inc (BIIB)
Days of sales outstanding (DSO)
Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | ||
---|---|---|---|---|---|---|
Receivables turnover | 5.91 | 5.97 | 7.09 | 7.03 | 7.65 | |
DSO | days | 61.75 | 61.17 | 51.50 | 51.96 | 47.74 |
December 31, 2023 calculation
DSO = 365 ÷ Receivables turnover
= 365 ÷ 5.91
= 61.75
To analyze Biogen Inc's Days Sales Outstanding (DSO) trend over the past five years, we observe a consistent increase in DSO from 2019 to 2023. The DSO has risen from 62.72 days in 2019 to 77.93 days in 2023. This indicates that the company is taking longer to collect its accounts receivable, which may point towards potential issues with the company's credit policies, collection efficiency, or changes in customer payment behavior. It is important for Biogen Inc to closely monitor its DSO and implement strategies to efficiently manage its accounts receivable to ensure optimal cash flow and liquidity.
Peer comparison
Dec 31, 2023
Company name
Symbol
DSO
Biogen Inc
BIIB
61.75
Amgen Inc
AMGN
113.38
Bio-Techne Corp
TECH
76.00
Gilead Sciences Inc
GILD
64.85
Halozyme Therapeutics Inc
HALO
—
Krystal Biotech Inc
KRYS
275.17
Moderna Inc
MRNA
54.95
Neurocrine Biosciences Inc
NBIX
85.14
Regenxbio Inc
RGNX
105.72
Repligen Corporation
RGEN
72.61
Vericel Corp Ord
VCEL
97.49